全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Induction of Apoptosis in the Human Prostate Cancer Cell Line DU-145 by a Novel Micronutrient Formulation

DOI: 10.4236/ojapo.2015.41002, PP. 11-21

Keywords: Prostate Cancer DU-145, NHDF, Apoptosis, Cytotoxicity, Caspase, MTT

Full-Text   Cite this paper   Add to My Lib

Abstract:

Prostate cancer, the most frequently diagnosed cancer in men, primarily affects males aged 55 and older and is more common in African Americans than Caucasians. Once the cancer has metastasized, current treatments are generally ineffective. We have identified a novel anti-neoplastic agent, a specifically designed nutrient mixture (NM), containing ascorbic acid, lysine, proline and green tea extract that demonstrates a broad spectrum of anti-tumor activity against a number of human cancer cell lines. In a previous study NM significantly inhibited prostate tumor in nude mice. In this study, we tested whether the formulation exerts its anti-tumor effects through induction of apoptosis on prostate cancer cell line DU-145. The effect of the nutrient mixture (NM) on cell growth inhibition in DU-145 cells was examined by 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Morphological changes and caspase activation associated with apoptosis induction was checked by H&E staining and Live Green Caspase assay, respectively. The NM was found to be slightly toxic to DU-145 cells at 100 μg/ml, but significantly toxic at 500 μg/ml and 1000 μg/ml. Percentage of cells undergoing apoptosis also increased from 6% at 100 μg/ml to 49% at 500 μg/ml and 83% at 1000 μg/ml, with greater number of cells showing morphological changes such as condensed nuclei and an acidophilic cytoplasm at higher concentrations. For the purpose of comparison, NM was also tested on a normal human dermal fibroblast (NHDF) cell line which exhibited far less apoptosis induction as compared to DU-145 cells. The percentage of cells undergoing apoptosis in case of NHDF cells was 7% at 100 μg/ml, 25.6% at 500 μg/ml and 76.5% at 1000 μg/ml. Our results demonstrate that the NM is effective in inhibiting cancer cell viability and inducing apoptosis in prostate cancer DU-145 cells and can thus be used as an effective treatment for prostate cancer.

References

[1]  Crawford, E.D. (2003) Epidemiology of Prostate Cancer. Urology, 62, S3-S12.
http://dx.doi.org/10.1016/j.urology.2003.10.013
[2]  Stewart, B.W. and Wild, C.P., Eds. (2014) World Cancer Report 2014. International Agency for Research on Cancer, Lyon.
[3]  Bishoff, J.T., Motley, G., Optenberg, S.A., Stein, C.R., Monn, K.A., Browning, S.M., Sabanagh, E., Foley, J.P. and Thompson, I.M. (1998) Incidence of Fecal and Urinary Incontinence Following Radical Perineal and Retropubic Prostatectomy in a National Population. The Journal of Urology, 160, 454-458.
http://dx.doi.org/10.1016/S0022-5347(01)62924-0
[4]  Melman, A., Boczko, J., Figueroa, J. and Leung, A.C. (2004) Critical Surgical Techniques for Radical Perineal Prostatectomy. The Journal of Urology, 171, 786-790.
http://dx.doi.org/10.1097/01.ju.0000107834.23316.59
[5]  Talcott, J.A., Manola, J., Clark, J.A., Kaplan, I., Beard, C.J., Mitchell, S.P., Chen, R.C., O’ Leary, M.P., Kantoff, P.W. and D’Amico, A.V. (2003) Time Course and Predictors of Symptoms after Primary Prostate Cancer Therapy. Journal of Clinical Oncology, 21, 3979-3986.
http://dx.doi.org/10.1200/JCO.2003.01.199
[6]  National Cancer Institute (2002) What You Need to Know about Prostate Cancer.
http://www.cancer.gov/cancerinfo/wyntk/prostate.
[7]  Conde, F.A. and Aronson, W.J. (2003) Risk Factors for Male Osteoporosis. Urologic Oncology, 21, 380-383. http://dx.doi.org/10.1016/S1078-1439(03)00109-1
[8]  Hori, S., Butler, E. and McLoughlin, J. (2011) Prostate Cancer and Diet: Food for Thought? British Journal of Urology International, 107, 1348-1359. http://dx.doi.org/10.1111/j.1464-410X.2010.09897.x
[9]  Willis, M.S. and Wians Jr., F.H. (2003) The Role of Nutrition in Preventing Prostate Cancer: A Review of the Proposed Mechanism of Action of Various Dietary Substances. Clinica Chimica Acta, 330, 57-83.
http://dx.doi.org/10.1016/S0009-8981(03)00048-2
[10]  Roomi, M.W., Ivanov, V., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2005) In Vivo Anti-Tumor Effect of Ascorbic Acid, Lysine, Proline and Green Tea Extract on Human Prostate Cancer PC-3 Xenografts in Nude Mice: Evaluation of Tumor Growth and Immunohistochemistry. In Vivo, 19, 179-183.
[11]  Hodges, R.E. (1980) Ascorbic Acid. In: Goodhart, R.S. and Shils, M.E., Eds., Modern Nutrition in Health and Disease, 6th Edition, Lea and Febiger, Philadelphia, 259-273.
[12]  Levine, M. (1986) New Concepts in the Biology and Biochemistry of Ascorbic Acid. New England Journal of Medicine, 314, 892-902. http://dx.doi.org/10.1056/NEJM198604033141407
[13]  Block, G. and Menkes, M. (1989) Ascorbic Acid in Cancer Prevention. In: Moon, T.E. and Micozzi, M.S., Eds., Diet and Cancer Prevention, Investigating the Role of Micronutrients, Marcel Dekker, Inc., New York, 341-388.
[14]  Block, G. (1991) Vitamin C and Cancer Prevention: The Epidemiologic Evidence. American Journal of Clinical Nutrition, 53, 270S-282S.
[15]  Hanck, A.B. (1988) Vitamin C and Cancer. Progress in Clinical and Biological Research, 259, 307-320.
[16]  Cameron, E. and Pauling, L. (1973) Ascorbic Acid and the Glycosaminoglycans: An Orthomolecular Approach to Cancer and Other Diseases. Oncology, 27, 181-192. http://dx.doi.org/10.1159/000224733
[17]  Cameron, E. and Pauling, L. (1974) The Orthomolecular Treatment of Cancer I. The Role of Ascorbic Acid in Host Resistance. Chemico-Biological Interactions, 9, 273-283.
http://dx.doi.org/10.1016/0009-2797(74)90018-0
[18]  Taper, H.S., Jamison, J.M., Gilloteaux, J., Gwin, C.A., Gordon, T. and Summers, J.L. (2001) In Vivo Reactivation of DNases in Implanted Human Prostate Tumors after Administration of a Vitamin C/K3 Combination. Journal of Histochemistry and Cytochemistry, 49, 109-119.
http://dx.doi.org/10.1177/002215540104900111
[19]  Jian, L., Xie, L.P., Lee, A.H. and Binns, C.W. (2004) Protective Effect of Green Tea against Prostate Cancer: A Case- Control Study in Southeast China. International Journal of Cancer, 108, 130-135.
http://dx.doi.org/10.1002/ijc.11550
[20]  Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G. and Corti, A. (2006) Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof of Principle Study. Cancer Research, 66, 1234-1240. http://dx.doi.org/10.1158/0008-5472.CAN-05-1145
[21]  Liao, S., Kao, Y.H. and Hiipakka, R.A. (2001) Green Tea: Biochemical and Biological Basis for Health Benefits. Vitamins and Hormones, 62, 1-94. http://dx.doi.org/10.1016/S0083-6729(01)62001-6
[22]  Liao, S., Umekita, Y., Guo, J., Kokontis, J.M. and Hiipakka, R.A. (1995) Growth Inhibition and Regression of Human Prostate and Breast Tumors in Athymic Mice by Tea Epigallocatechin Gallate. Cancer Letters, 96, 239-243. http://dx.doi.org/10.1016/0304-3835(95)03948-V
[23]  Valcic, S., Timmerman, B.N., Alberts, D.S., Wachter, G.A., Krutzch, M., Wymer, J. and Guillen, J.M. (1996) Inhibitory Effects of Six Green Tea Catechins and Caffeine on the Growth of Four Selected Human Tumor Cell Lines. Anticancer Drugs, 7, 461-468. http://dx.doi.org/10.1097/00001813-199606000-00011
[24]  Mukhtar, H. and Ahmed, N. (2000) Tea Polyphenols: Prevention of Cancer and Optimizing Health. American Journal of Clinical Nutrition, 71, 1698S-1720S.
[25]  Yang, G.Y., Liao, J., Kim, K., Yurkow, E.J. and Yang, C.S. (1998) Inhibition of Growth and Induction of Apoptosis in Human Cancer Cell Lines by Tea Polyphenols. Carcinogenesis, 19, 611-616.
http://dx.doi.org/10.1093/carcin/19.4.611
[26]  Clark, L.C., Dalkin, B., Krongrad, A., Combs Jr., G.F., Turnbull, B.W., Slate, E.H., et al. (1998) Decreased Incidence of Prostate Cancer with Selenium Supplementation: Results of a Double-Blind Cancer Prevention Trial. British Journal of Urology, 81, 730-734.
[27]  Duffield-Lillico, A.J., Dalkin, B.L., Reid, M.E., Turnbull, B.W., Slate, E.H., Jacobs, E.T., et al. (2003) Selenium Supplementation, Baseline Plasma Selenium Status and Incidence of Prostate Cancer: An Analysis of the Complete Treatment Period of the Nutritional Prevention of Cancer Trial. British Journal of Urology International, 91, 608-612. http://dx.doi.org/10.1046/j.1464-410X.2003.04167.x
[28]  Marshall, J.R., Tangen, C.M., Sakr, W.A., Wood, D.P., Berry, D.L., Klein, E.A., et al. (2011) Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High Grade Prostatic Intra-Epithelial Neoplasia: SWOG S9917. Cancer Prevention Research, 4, 1761-1769.
http://dx.doi.org/10.1158/1940-6207.CAPR-10-0343
[29]  Algotar, A.M., Stratton, M.S., Ahmann, F.R., Ranger-Moore, J., Nagle, R.B., Thompson, P.A., et al. (2013) Phase 3 Clinical Trial Investigating the Effect of Selenium Supplementation in Men at High Risk of Prostate Cancer. Prostate, 73, 328-335. http://dx.doi.org/10.1002/pros.22573
[30]  Ulrike, P. and Takata, Y. (2008) Selenium and the Prevention of Prostate and Colorectal Cancer. Molecular Nutrition and Food Research, 52, 1261-1272. http://dx.doi.org/10.1002/mnfr.200800103
[31]  Netke, S.P., Roomi, M.W., Ivanov, V., Niedzwiecki, A. and Rath, M. (2003) A Specific Combination of Ascorbic Acid, Lysine, Proline and Epigallocatechin Gallate Inhibits Proliferation of Extracellular Matrix Invasion of Various Human Cancer Cell Lines. Research Communications in Pharmacology and Toxicology: Emerging Drugs, 2, 37-50.
[32]  Roomi, W., Roomi, N., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2010) In Vivo and In Vitro Effect of a Nutrient Mixture on Human Hepatocarcinoma Cell Line SK-HEP-1. Experimental Oncology, 32, 84-91.
[33]  Roomi, W., Kalinovsky, T., Cha, J., Roomi, N., Niedzwiecki, A. and Rath, M. (2014) Effects of a Nutrient Mixture on Immunohistochemical Localization of Cancer Markers in Human Cervical Cancer HeLa Cell Tumor Xenografts in Female Nude Mice. Experimental and Therapeutic Medicine. (In Press)
[34]  Roomi, W., Ivanov, V., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2005) In Vivo Anti-Tumor Effect of Ascorbic Acid, Lysine, Proline and Green Tea Extract on Human Colon Cancer Cell HCT 116 Xenografts in Nude Mice: Evaluation of Tumor Growth and Immunohistochemistry. Oncology Reports, 13, 421-425.
[35]  Roomi, W., Ivanov, V., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2005) In Vitro and in Vivo Anti-Tumorigenic Activity of Lysine, Proline, Ascorbic Acid and Green Tea Extract on Human Breast Cancer Cell Lines MDA-MB-231 and MCF7. Medical Oncology, 22, 129-138. http://dx.doi.org/10.1385/MO:22:2:129
[36]  Roomi, W., Ivanov, V., Netke, S., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2006) In Vivo and in Vitro Anti-Tumor Effect of Ascorbic Acid, Lysine, Proline and Green Tea Extract on Human Melanoma Cell Line A2058. In Vivo, 20, 25-32.
[37]  Roomi, W., Ivanov, V., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2007) Inhibition of Cell Invasion and MMP Production by a Nutrient Mixture in Malignant Liposarcoma Cell Line SW-872. Medical Oncology, 24, 394-401. http://dx.doi.org/10.1007/s12032-007-0022-z
[38]  Roomi, W., Ivanov, V., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2005) Anti-Tumor Effect of Nutrient Synergy on Human Osteosarcoma Cells U-2OS, MNNG-HOS and Ewing’s Sarcoma SK-ES.1. Oncology Reports, 13, 253-257.
[39]  Roomi, W., Ivanov, V., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2004) Anti-Tumor Effect of Ascorbic Acid, Lysine, Proline, Arginine, and Epigallocatechin Gallate on Prostate Cancer Cell Lines PC-3, LNCaP, and DU-145. Research Communications in Molecular Pathology and Pharmacology, 115-116, 251-264.
[40]  Roomi, M.W., Ivanov, V., Netke, S.P., Niedzwiecki, A. and Rath, M. (2003) Serum Markers of the Liver, Heart, and Kidney and Lipid Profile and Histopathology in ODS Rats Treated with Nutrient Synergy. Journal of the American College of Nutrition, 22, 477.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413